[
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=38de75c6321a7182157b434deea79fc2c84c57e99758af2c5f6aee15a535d3d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751634003,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 135755715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=38de75c6321a7182157b434deea79fc2c84c57e99758af2c5f6aee15a535d3d1"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations",
    "summary": "an aggressive and currently incurable disease sta...",
    "url": "https://finnhub.io/api/news?id=ae8f88f6e4d750c7ed5e99748e19c15f01659f0fd9aa974e2c7f502d37eedaaa",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751620400,
      "headline": "Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations",
      "id": 135752476,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "an aggressive and currently incurable disease sta...",
      "url": "https://finnhub.io/api/news?id=ae8f88f6e4d750c7ed5e99748e19c15f01659f0fd9aa974e2c7f502d37eedaaa"
    }
  },
  {
    "ts": null,
    "headline": "North America Beta-Glucan Market Forecast and Company Analysis Report 2025-2033 Featuring Koninklijke Philips, EDAP TMS, Johnson & Johnson, Medtronic, Hitachi, Theraclion, Stryker, and GE",
    "summary": "The North America Beta Glucan Market, valued at USD 204.03 million in 2024, is poised to grow to USD 373.85 million by 2033, with a CAGR of 6.96% from 2025 to 2033. This growth is driven by rising consumer demand for immune-boosting and functional food ingredients and increased awareness of beta glucan's health benefits. Beta glucan—a soluble fiber found in grains, fungi, and yeast—offers cholesterol-reducing and immune-modulating properties, gaining traction in functional foods, nutraceuticals,",
    "url": "https://finnhub.io/api/news?id=9a695f3816acc6952f8e0f678e70f27b0d26658dc6967d150502d81d85dce021",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751617140,
      "headline": "North America Beta-Glucan Market Forecast and Company Analysis Report 2025-2033 Featuring Koninklijke Philips, EDAP TMS, Johnson & Johnson, Medtronic, Hitachi, Theraclion, Stryker, and GE",
      "id": 135749159,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The North America Beta Glucan Market, valued at USD 204.03 million in 2024, is poised to grow to USD 373.85 million by 2033, with a CAGR of 6.96% from 2025 to 2033. This growth is driven by rising consumer demand for immune-boosting and functional food ingredients and increased awareness of beta glucan's health benefits. Beta glucan—a soluble fiber found in grains, fungi, and yeast—offers cholesterol-reducing and immune-modulating properties, gaining traction in functional foods, nutraceuticals,",
      "url": "https://finnhub.io/api/news?id=9a695f3816acc6952f8e0f678e70f27b0d26658dc6967d150502d81d85dce021"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds",
    "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, remained optimistic about Johnson & Johnson (NYSE:JNJ) shares, rating it as a Buy on June 5. The analyst noted several factors that lead to the update. Similar to its industry peers, the company demonstrates a proactive approach […]",
    "url": "https://finnhub.io/api/news?id=83c2fd7de6b6ab3b7767f478e9ec57201c39d0fbdd714e21a342c52456c8b956",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751613777,
      "headline": "Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds",
      "id": 135749160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, remained optimistic about Johnson & Johnson (NYSE:JNJ) shares, rating it as a Buy on June 5. The analyst noted several factors that lead to the update. Similar to its industry peers, the company demonstrates a proactive approach […]",
      "url": "https://finnhub.io/api/news?id=83c2fd7de6b6ab3b7767f478e9ec57201c39d0fbdd714e21a342c52456c8b956"
    }
  }
]